Kałas Maria, Stępniewska Ewelina, Gniedziejko Michał, Leszczyński-Czeczatka Jakub, Siemiński Mariusz
Department of Emergency Medicine, Medical University of Gdańsk, 80-214 Gdańsk, Poland.
Emergency Department, University Clinical Center, 80-952 Gdańsk, Poland.
J Clin Med. 2025 Apr 30;14(9):3122. doi: 10.3390/jcm14093122.
Glucagon-like peptide-1 Receptor Agonists (GLP-1 RAs) have been one of the most discussed issues in medicine for the past few years. Initially dedicated to patients with type 2 diabetes mellitus (T2DM), the medicine turned out to be an effective weight-loss treatment for people beyond this population. Whereas their beneficial somatic and metabolic effect are beyond doubt, their possible psychiatric adverse reactions have raised concerns. Eating disorders (EDs) are among the mental illnesses whose number is increasing worldwide. Thus, this review aims to summarize the status of knowledge on the correlation between the popularity of GLP-1 RAs and EDs. The conclusions are not unequivocal, pointing out that GLP-1 ARs have the potential to be an effective therapeutic option in some cases of Eds, but if used inappropriately, may increase morbidity of eating disorders.
在过去几年里，胰高血糖素样肽-1受体激动剂（GLP-1 RAs）一直是医学领域讨论最多的话题之一。这种药物最初是针对2型糖尿病（T2DM）患者研发的，但后来发现它对该人群以外的人也是一种有效的减肥治疗方法。尽管它们有益的躯体和代谢作用毋庸置疑，但其可能的精神科不良反应却引发了人们的关注。饮食失调（EDs）是全球范围内发病率不断上升的精神疾病之一。因此，本综述旨在总结关于GLP-1 RAs的普及与EDs之间相关性的知识现状。结论并不明确，指出GLP-1 ARs在某些饮食失调病例中有可能成为一种有效的治疗选择，但如果使用不当，可能会增加饮食失调的发病率。
